Suvorexant in Insomnia Co-morbid With Fibromyalgia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02684136|
Recruitment Status : Recruiting
First Posted : February 17, 2016
Last Update Posted : February 22, 2018
|Condition or disease||Intervention/treatment||Phase|
|Insomnia Fibromyalgia||Drug: suvorexant Drug: placebo||Phase 4|
It has now become clear that the relation of sleep and pain is bidirectional; acute and chronic pain is associated with disturbed sleep and disturbed sleep enhances pain. Experimental studies have shown that reduced and fragmented sleep in pain-free normals increases their pain sensitivity and daily self-report studies in chronic pain patients have shown a poor night of sleep is followed by enhanced next-day pain. In mediation analyses of large clinical data sets it is found that the sleep-pain side of the bidirectional relation, as opposed to the pain-sleep side, accounts for the greater variance. These data then would suggest that improving sleep in chronic pain disorders should attenuate daytime pain.
Most of the drugs used to treat chronic pain facilitate inhibitory central nervous system mechanisms as their primary mechanism of action. Suvorexant, recently approved by the FDA for the treatment of insomnia characterized by difficulties with sleep onset and sleep maintenance, has a unique mechanism of action. Suvorexant is a selective antagonist for orexin receptors (OX1R and OX2R). Orexins are considered to be involved in arousal and maintenance of the waking state.
As such, suvorexant may provide unique clinical benefit as a treatment in chronic pain conditions with co-morbid insomnia, and specifically for fibromyalgia with its putative central hyperarousal and hypersensitization. Thus, this project proposes to study objective and clinical measures of sleep, pain, and daytime sleepiness and fatigue in patients with fibromyalgia and co-morbid insomnia while treated short-term with suvorexant 20 mg versus placebo.
Those qualifying will receive suvorexant 20 mg and placebo for each of 9 nights in a cross over design with 7 nights of washout between treatments. Overnight sleep recordings (PSGs) will be collected on nights 7 and 8 of each crossover treatment arm to determine objective sleep measures. During the day following night 7 in each arm, a Multiple Sleep Latency Test (MSLT) at 1000, 1200, 1400, and 1600 hr will be conducted and nociceptive sensitivity [finger withdrawal latency (FWL)] testing to a radiant heat stimulus (1100 and 1500 hr) will be conducted on day 1 and day 8. Self-reported mood and pain indices will also be completed prior to each FWL test.
Primary outcomes to be measured include PSG sleep efficacy and FWL response on both conditions (suvorexant 20 mg versus placebo).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia|
|Study Start Date :||February 1, 2016|
|Estimated Primary Completion Date :||September 30, 2018|
|Estimated Study Completion Date :||September 30, 2018|
9 nights of 20 mg suvorexant
suvorexant 20 mg taken before sleep
Other Name: belsomra
Placebo Comparator: placebo
9 nights placebo
placebo taken before sleep
Other Name: matching placebo
- polysomnographic assessment of sleep [ Time Frame: continuous sleep recording from 11pm to 7am on night 8 ]total sleep time on 8 hr standard sleep recording
- daytime pain sensitivity [ Time Frame: testing at 1100 and 1500 hrs on day 1 and day 8 ]finger withdrawal response to a radiant heat stimulus when pain is first experienced
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02684136
|Contact: Dana Withrow, MHAfirstname.lastname@example.org|
|Contact: Gail Koshorek, BSemail@example.com|
|United States, Michigan|
|HFHS Sleep Disorders Ctr||Recruiting|
|Detroit, Michigan, United States, 48202|
|Contact: Gail Koshorek, BS 313-916-5179 firstname.lastname@example.org|
|Contact: Dana Withrow, MHA 313-916-5302 email@example.com|
|Principal Investigator:||Timothy Roehrs, PhD||Henry Ford Health System|
|Study Chair:||Thomas Roth, PhD||Henry Ford Health System|